Vukosi Treasure Makondo

Mr. Vukosi Treasure Makondo

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
KKKabelo Gabriel Kaapu
Kabelo Gabriel Kaapu
VMVukosi Treasure Makondo
Vukosi Treasure Makondo
Emilyn Costa ConceicaoEmilyn Costa Conceicao
Emilyn Costa Conceicao
IRIvy Rukasha
Ivy Rukasha
Background: Bedaquiline (BDQ) resistance poses a serious threat to its long-term efficacy, particularly in high-burden settings like South Africa, where data remain scattered and largely non-synthesized. Objective: This study aimed to estimate the trends of BDQ resistance in drug resistant tuberculosis (DR-TB), characterize associated resistance mechanisms, and evaluate implications for treatment outcomes in South Africa. Eligibility criteria: We included primary studies reporting BDQ resistance, resistance mechanisms, minimum inhibitory concentrations (MICs), or treatment outcomes among patients with MDR- or XDR-TB treated with BDQ-containing regimens in South Africa. Information sources: PubMed, Web of Science, and Embase were searched for studies published between January 2016 and July 2024. Risk of bias: Study quality was assessed using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist. Synthesis of results: Random-effects meta-analysis with Freeman–Tukey double-arcsine transformation was used to estimate pooled BDQ resistance prevalence. Heterogeneity, sensitivity analyses, and publication bias were assessed. Results: Twenty-eight studies were included. The pooled prevalence of BDQ resistance was 6.0% (95% CI: 4.1–7.9%; I2 = 62%). Treatment success averaged 63.5%, and culture conversion reached 84.1%. Resistance-associated mutations were most frequently reported in Rv0678, followed by atpE and pepQ, often associated with elevated MICs (≥2–4 μg/mL). Evidence of small-study effects was observed (Egger’s test, p = 0.0012). A pooled prevalence estimate was calculated; however, evidence of small-study effects suggests that estimates should be interpreted cautiously. Limitations: Heterogeneity in study design, outcome definitions, and resistance testing methods limited comparability across studies. Conclusions: Bedaquiline remains effective for DR-TB treatment in South Africa; however, emerging resistance and its molecular drivers pose a growing threat to regimen sustainability, including BPaL. Strengthened surveillance and standardized resistance testing are urgently needed.

28 May 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
KKKabelo Gabriel Kaapu
Kabelo Gabriel Kaapu
VMVukosi Treasure Makondo
Vukosi Treasure Makondo
Emilyn Costa ConceicaoEmilyn Costa Conceicao
Emilyn Costa Conceicao
IRIvy Rukasha
Ivy Rukasha
Background: The success of modern drug-resistant tuberculosis (DR-TB) regimens increasingly depends on linezolid (LZD) and pretomanid (Pa), yet the emergence of resistance to these critical agents threatens to reverse recent treatment advances, with limited consolidated evidence available from high-burden settings such as South Africa. Objectives: To systematically review and meta-analyse South African data on LZD and Pa resistance, minimum inhibitory concentrations (MICs), resistance-associated mutations, and treatment outcomes. Eligibility Criteria: We included clinical trials, cohort studies, surveillance studies, and molecular investigations conducted in South Africa from 2013 onward that reported resistance prevalence, MIC data, genotypic mutations, or treatment outcomes related to LZD and/or Pa. Information Sources: PubMed, PubMed, Embase, Web of Science, and grey literature sources were searched from January 2013 to 31 December 2025 in accordance with PRISMA 2020 guidelines. Risk of Bias: Study quality was assessed using the Joanna Briggs Institute (JBI) cohort appraisal checklist. Included Studies: Seventeen studies representing provincial and national cohorts were included. Synthesis of Results: Random-effects meta-analysis was used to estimate pooled baseline resistance. Subgroup, sensitivity, and meta-regression analyses were performed. Results: Random-effects meta-analysis demonstrated a pooled baseline LZD resistance prevalence of 0.53% (95% CI: 0.01–1.83; I2 = 81.1%) in routine South African cohorts, while substantially higher resistance (33%) was observed in treatment-failure populations. Baseline LZD MICs were typically 0.125–1.0 µg/mL, while elevated MICs (up to 8.0 µg/mL) were associated with rplC and rrl mutations, particularly rplC Cys154Arg. No confirmed phenotypic Pa resistance was identified across included South African cohorts, despite the detection of resistance-associated mutations in genomic surveillance studies. MIC values remained within the range of 0.016–1.0 µg/mL. Mutations in ddn, fbiA, fbiC, and fgd1 were reported in genomic studies. Treatment success rates ranged from 63.6% to 99% for LZD-containing regimens and approached 90% for Pa-based regimens. Limitations: Limited study numbers, heterogeneity in laboratory methods, and overrepresentation of certain provinces may affect generalizability. Conclusions: Baseline resistance to LZD and Pa in South Africa remains low, supporting continued programmatic use. Ongoing molecular surveillance is essential to detect resistance amplification and preserve regimen efficacy.